What acetyl hexapeptide-8 is

Acetyl hexapeptide-8 (formerly INCI: Acetyl Hexapeptide-3; widely known by the trade name Argireline) is a synthetic short peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2. Both ends are capped — N-terminal acetylation and C-terminal amidation — specifically to resist degradation by aminopeptidases and carboxypeptidases on the skin surface.

It belongs to the "signal peptide / neurotransmitter-inhibiting peptide" family, entirely different in mechanism from palmitoyl pentapeptide-4 (Matrixyl, which pushes collagen synthesis) or copper tripeptide-1 (which works on repair). Hexapeptide-8 addresses the muscle-contraction step — not collagen loss nor barrier damage. Getting that distinction right is the first formulation decision to make.

Physico-chemically it is a highly water-soluble, ≈889 Da, heat- and pH-sensitive hydrophilic active. Those three traits confine it almost entirely to water phases and aqueous gel systems — and explain why it needs extra penetration and stability work in oil-rich formats such as eye creams.

Ingredient fact box

How it works, plainly

Picture an expression line as a four-link chain: nerve fires → acetylcholine is released → muscle contracts → skin folds into a line. Hexapeptide-8 jams the second link.

• It mimics a fragment of SNAP-25. To release acetylcholine, a nerve ending needs the SNARE complex (assembled from SNAP-25, syntaxin, synaptobrevin and partners) to dock the transmitter-loaded vesicle to the membrane. Acetyl hexapeptide-8 closely resembles the N-terminal fragment of SNAP-25: it occupies the position but cannot do the job, leaving the complex incompletely assembled, vesicle fusion less efficient, and acetylcholine release reduced.
• Less release, smaller contraction. With a weaker contractile signal, the orbicularis oculi muscle contracts less strongly when smiling or squinting, the skin is folded less forcefully, and the look of dynamic lines softens. Note this is a reduction in amplitude, not paralysis — it is reversible, mild and confined to the site of application.
• Only for lines made by movement. For lines already fixed and visible at rest (static lines), or those caused by photo-ageing and volume loss, this is the wrong pathway. Hand those to retinoids, pro-xylane, humectants and sun protection working together.

An honest caveat: while the SNARE / SNAP-25 pathway itself is well-established neurobiology, human efficacy evidence for acetyl hexapeptide-8 rests largely on supplier studies and small, short instrumental trials, with limited peer-reviewed literature — much of it supplier-funded. Search PubMed for "acetyl hexapeptide-8", "SNARE" and "SNAP-25" to verify independently. Claims should therefore read "helps reduce the look of expression lines and fine lines" — never "removes wrinkles" or "replaces injections".

Best-fitting formats

Use level and formulation notes (verify by bench trial)

Common reference level: commercial hexapeptide-8 is supplied mainly as an aqueous solution, and active peptide content varies widely between suppliers. Supplier guidance for the solution as supplied usually falls in the 3%–10% range. To work in pure-peptide terms, convert using the active content on the supplier COA and confirm on the bench.

• pH is constraint #1. Keep it at 5.0–7.0; below 4 or above 8 accelerates degradation and deamidation, with visible activity loss over shelf life.
• Temperature is constraint #2. Add below 40 °C and avoid prolonged heat; post-emulsification addition at low temperature is the safest route.
• Preservation decides the outcome. Peptides are an excellent nitrogen source for microbes. If the preservative system is weak, microbial proteases will simply digest the peptide — this is the usual reason a formula "contains it but tests negative for it". Run a preservative challenge test.
• Incompatibilities. Avoid long-term coexistence with strong oxidisers, high levels of reducing agents or aggressive chelating systems; high-ethanol systems may precipitate the peptide or alter its conformation.
• Penetration design. A hydrophilic 889 Da molecule crosses the barrier poorly. Consider polyols, liposomal carriers or penetration enhancers — and assess eye-area tolerance.
• Order of addition. Dissolve the peptide fully in purified water or a polyol–water solution first, fold into the bulk at the low-temperature stage, then adjust pH and make up to volume.
• Stability protocol. 40 °C for 3 months plus freeze–thaw (−15 °C ↔ 40 °C, ≥3 cycles), and measure actual peptide content by HPLC or amino-acid analysis — appearance alone proves nothing.

The figures above are common reference levels for eye care formulas; the actual use level is set by the formulation engineer based on dosage form, compatibility and target-market rules. Permitted use conditions, limits and labelling requirements differ by market — complete a compliance review for each destination before shipment. All descriptions here are general cosmetic applications and appearance or skin-feel statements, not medical advice or efficacy guarantees.

Compliance and market notes (verify per target market)

• China: for this synthetic peptide first verify its listing status and historical maximum use level in the Inventory of Existing Cosmetic Ingredients in China (2021 edition). Claims must comply with the Cosmetic Supervision and Administration Regulation, cosmetic labelling rules and efficacy-claim evaluation rules; "anti-wrinkle" or "firming" claims require substantiation on file.
• EU (EC) No 1223/2009: declare the ingredient and its impurity profile accurately in the CPNP notification, PIF and CPSR. Claims must meet the Common Criteria for Cosmetic Claims, (EU) No 655/2013 — no implied pharmacological or injectable-like effect.
• US MoCRA (2022): facility registration, product listing, safety substantiation, adverse-event reporting and record-keeping apply, with labelling under the FD&C Act and relevant 21 CFR provisions. Cosmetic ingredients and finished products generally do not undergo pre-market approval — never write "FDA approved".
• Claim red lines: phrases such as "topical botox", "injection alternative", "wrinkle removal", "eliminates wrinkles" or "medical" are off-limits. Equating the effect to injectable neuromodulators is treated as misleading in most markets.
• Japan / Korea / Middle East: each follows its own cosmetic or quasi-drug pathway with different boundaries and limits — verify per target market.

Ingredient pairings

• Hexapeptide-8 + sodium hyaluronate (0.1%–0.5%): the classic complement. The peptide handles long-term expression-line management while hyaluronic acid delivers instant hydration and plumpness, so the product feels like something from the very first use.
• Hexapeptide-8 + panthenol (1%–3%) / Centella asiatica extract: soothing and moisturising, improving periorbital tolerance for gentle, high-frequency daily lines.
• Hexapeptide-8 + niacinamide (2%–5%): barrier support and brightening, suited to eye creams and serums positioned as "early-ageing defence + radiance".
• Hexapeptide-8 + caffeine (1%–3%): one addresses dynamic lines, the other the look of puffiness — a sensible morning-scenario pairing.
• Use with care: combining with high-level AHAs/BHAs compresses the peptide's stability window — separate the systems or stagger use. Formulating alongside retinol requires both stability and tolerance work; in practice split lines or split timing beats putting both at high level in one bottle.

Formulation pairing cards

FAQ

Image briefs